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Objectives This study sought to evaluate short- and long-term outcomes of patients undergoing
emergency percutaneous coronary intervention (PCI) for acute myocardial infarction due to a culprit
lesion in an unprotected left main coronary artery.
Methods In this retrospective, 2-center, international observational study, 5,261 patients were ad-
mitted between February 2005 and December 2008 with acute myocardial infarction and treated
with PCI; of these, 1,277 were ST-segment elevation myocardial infarction and 3,984 non–ST-seg-
ment elevation myocardial infarction. We identiﬁed 48 patients among this cohort who underwent
emergency PCI to an unprotected left main coronary artery culprit lesion.
Results Mean age was 70  12.5 years, and 45% of the patients presented with ST-segment elevation
myocardial infarction or new left bundle branch block. Cardiogenic shock was present in 45%, and distal
left main coronary artery disease was present in 71% of patients. Angiographic procedural success was
achieved in 92% of patients. Overall in-hospital mortality was 21%, due in all cases to refractory, multior-
gan failure. Twenty-ﬁve percent experienced major adverse cardiac events, deﬁned as death, myocardial
infarction, stent thrombosis, and target vessel revascularization. In patients presenting in cardiogenic
shock, in-hospital mortality was 32%. At 1-year follow-up, in-hospital survivors had a mortality rate of
10.5%, whereas 18.4% experienced subsequent major adverse cardiac events. Long-term prognosis was
excellent in hospital survivors with a 1-year survival rate of 89.5%.
Conclusions Patients with acute myocardial infarction and thrombosis of the unprotected left main
coronary artery are a high-risk subgroup with a substantial mortality, particularly if they present in
cardiogenic shock. We demonstrate that in these patients, PCI is a feasible treatment option associ-
ated with reasonably good outcomes. Long-term prognosis is excellent in hospital survivors with an
89.5% survival rate at 1 year. (J Am Coll Cardiol Intv 2011;4:618–26) © 2011 by the American
College of Cardiology Foundation
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619Between 4% and 7% of patients with acute myocardial
infarction (AMI) have significant involvement of the left
main coronary artery (LMCA) (1,2). Patients with AMI
due to thrombosis within an unprotected left main coronary
artery (ULMCA) are a small but critically ill subgroup,
characterized by frequent presentation with cardiogenic
shock and high in-hospital major adverse cardiac event
(MACE) rates (3,4). The standard revascularization strat-
egy for patients with significant disease in a ULMCA is
coronary artery bypass graft (CABG) surgery (5). Such a
strategy, however, carries very high mortality and morbidity
in patients presenting with AMI and ULMCA thrombosis
(6). Traditionally, significant disease of a ULMCA has been
considered a relative or absolute contraindication to percuta-
neous transluminal coronary angioplasty, with or without
bare-metal stenting, because of high rates of abrupt vessel
closure, restenosis, and target vessel revascularization (7–11).
Improved results have been reported with drug-eluting stents
(DES), with a 1-year mortality rate between 0% and 4%
(12–18). However, the available data on the short- and
long-term outcomes of percutaneous coronary intervention
(PCI) on LMCA lesions in the setting of AMI is very limited
and mainly derived from small registry studies, often from
single centers, consisting of between 12 and 40 patients
(19–25). Indeed, even in the most recent data from GRACE
(Global Registry of Acute Coronary Events), only 41 of 514
patients with ULMCA who underwent PCI in the setting of
an acute coronary syndrome (ACS) had LMCA disease alone
as a culprit lesion (26), and less than one-half of the patients
treated with a PCI strategy underwent revascularization on the
day of admission. Thus, outcomes associated with urgent
revascularization in the emergency setting remain largely un-
defined.
The aim of the present retrospective analysis is to
evaluate the short- and long-term outcomes associated
with PCI to culprit ULMCA lesions in patients with
AMI.
Methods
Patient population. We retrospectively analyzed 48 consec-
utive patients presenting with AMI to San Giovanni Hos-
pital, Rome, Italy, and Manchester Royal Infirmary, Man-
chester, United Kingdom, from February 2005 to December
2008, who were treated with emergency PCI to a culprit
ULMCA lesion. The decision to proceed to emergency
cardiac catheterization was based on the presence of pro-
longed (30 min)/ongoing chest pain, coupled with elec-
trocardiogram changes of acute ST-segment elevation myo-
cardial infarction (STEMI), new/presumed new left bundle
branch block, or persistent, widespread ST-segment depres-
sion refractory to medical therapy (non–ST-segment elevation
myocardial infarction [NSTEMI]), with or without cardio- igenic shock. Over the same period, 5,261 patients were
treated at the 2 centers with PCI for ACS, 1,277 with
STEMI and 3,984 with NSTEMI. All patients at San
Giovanni Hospital (n  36) underwent PCI due to the
absence of cardiac surgical support at that hospital, whereas
those at the Manchester Royal Infirmary (n  12) were
initially discussed with the cardiothoracic surgeons but were
turned down due to a perceived high surgical risk.
Percutaneous coronary intervention. Aspirin was adminis-
ered as a 250-mg intravenous bolus to all patients present-
ng to San Giovanni Hospital, at
he referring center, in the am-
ulance, or upon arrival at the
ospital. In contrast, aspirin was
dministered as a 300-mg oral
ose at the point of first medical
ontact in all patients presenting
o the Manchester Royal Infir-
ary. Clopidogrel was adminis-
ered as a 600-mg oral loading
ose at the first point of medical
ontact before the procedure. Gly-
oprotein IIb/IIIa inhibitors were
dministered in all patients present-
ng with STEMI and in 3 patients
resenting with NSTEMI. Unfrac-
ionated heparin was administered
s a weight-adjusted intravenous or
ntra-arterial bolus given at the time
f PCI. An intravenous infusion of
eparin was also given to patients
equiring an intra-aortic balloon
ump (IABP).
Demographics and follow-up.
Demographic, procedural, and
outcome data were obtained
from review of the catheteriza-
tion laboratory database as well
as the case notes at the 2 centers.
All angiograms were reviewed by
each set of authors at each re-
spective center to confirm angio-
graphic findings and outcomes.
Clinical follow-up was obtained
in all patients through outpatient clinic visits and/or tele-
phone interviews. Routine follow-up angiography was per-
formed in 44% of patients.
Endpoints and study deﬁnitions. MACE was assessed dur-
ng hospitalization and at follow-up and was defined as
eath, recurrent myocardial infarction (re-AMI), stent throm-
osis (ST), and target vessel revascularization during hospital-
zation and at 1-year follow-up. Myocardial infarction was
efined as cardiac sounding chest pain associated with a rise
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
AMI  acute myocardial
infarction
CABG  coronary artery
bypass graft
DES  drug-eluting stent(s)
IABP  intra-aortic balloon
pump(s)
LAD  left anterior
descending artery
LCX  left circumflex artery
LMCA  left main coronary
artery
MACE  major adverse
cardiac event(s)
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
RCA  right coronary artery
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
ULMCA  unprotected left
main coronary arteryn serum troponin (T or I) level exceeding the 99th percentile
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620of a normal reference population  new electrocardiogram
changes (ST-segment elevation or depression 1 mm,
T-wave changes, or left bundle branch block) in 2 or more
contiguous leads (27). Cardiogenic shock was defined as
sustained hypotension (systolic blood pressure 90 mm
Hg) with signs of tissue hypoperfusion including cool
extremities, oliguria (30 ml/h), and altered level of con-
sciousness. The LMCA was considered “unprotected” if
there was no previous history of CABG, or if CABG had
been performed, but no patent grafts were demonstrated on
angiography. PCI was defined as angiographically successful
when the residual diameter stenosis was 20% and TIMI
(Thrombolysis In Myocardial Infarction) flow grade 3 was
achieved in the main vessel and its major branches. Binary
restenosis was considered present when a stenosis 50% at
the segment site (intrastent and 5 mm proximal and distal to
the stent) was observed at follow-up coronary angiography
regardless of the clinical symptomatology of the patient.
Stent thrombosis was classified according to the Academic
Research Consortium definition as definite, probable, or
possible; and as early (0 to 30 days), late (31 to 360 days),
and very late (360 days) (28). Briefly, definite ST requires
the presence of an acute coronary syndrome with angio-
graphic or autopsy evidence of thrombus or occlusion. In
contrast, probable ST is defined as any unexplained cardiac
death within 30 days after the index procedure or AMI
involving the target vessel territory without angiographic
confirmation, whereas possible ST is defined as unexplained
cardiac death occurring at least 30 days after the index
procedure.
Target lesion revascularization was defined as any revas-
cularization performed on the treated segment, whereas
target vessel revascularization was defined as any reinterven-
tion performed on any segment of the treated vessel. Target
lesion revascularization of the distal LMCA was defined as
revascularization to treat a stenosis 50% within 5 mm
distal to the left main bifurcation including the ostium of
the left anterior descending artery and/or left circumflex
artery. Deaths were classified as either cardiac or noncardiac.
Sudden death or deaths of unknown cause were considered
cardiac.
Statistical analysis. All data are presented as mean  SD.
Categorical variables were compared using Fisher exact test.
Univariate logistic regression analysis was performed with
death as the dependent variable. Independent variables
studied included: age 60 years, presentation with cardio-
genic shock, DES use, diabetes, glycoprotein IIb/IIIa in-
hibitor use, left main stem ostial lesion, left main stem distal
lesion, significant right coronary artery (RCA) involvement,
multivessel stenting, presence of collaterals, IABP use, and
clinical presentation with STEMI. Multivariate stepwise
logistic regression analysis was performed in which inde-
pendent variables were removed from the model if p  0.1.Results
Baseline clinical data. Demographic and clinical character-
stics of 48 consecutive patients undergoing PCI to a
LMCA at the 2 centers following presentation with
TEMI/NSTEMI are presented in Table 1. The mean age
f the cohort treated was 70  12.5 years. Of these, 12
atients (25%) had a prior history of diabetes mellitus, 22
atients (45%) presented with STEMI, whereas the re-
aining 26 patients (55%) presented with NSTEMI. A
otal of 22 patients (45%) were in cardiogenic shock upon
rrival in the catheterization laboratory, and of these, 13
59.1%) presented with NSTEMI, and 9 (40.9%) presented
ith STEMI.
A significant proportion of patients required circulatory
nd/or ventilatory support as evidenced by use of IABP in
4% of cases, orotracheal intubation with assisted ventila-
ion in 20% of cases, and pharmacological inotropic support
n 37% of cases. The latter 2 were only used in cardiogenic
hock cases, whereas IABP was used in all cardiogenic shock
ases in addition to 4 cases without cardiogenic shock, either
rophylactically or because of hemodynamic instability that
eveloped during the procedure.
Angiographic and procedural characteristics. The angio-
raphic and procedural characteristics are presented in
ables 2 and 3. The LMCA was judged the culprit vessel in
ll patients, and distal involvement was the most common
nding (71%) (Table 2). Significant coexistent disease of the
CA was documented in 26 patients (54%). Of the 12
atients in whom the RCA was completely occluded, 7 were
n cardiogenic shock. Significant left anterior descending
LAD) and left circumflex (LCX) artery disease was present
n 32 (66.6%) and 21 (43.7%) patients, respectively.
Multivessel PCI was performed in 23 (48%) patients, as
ummarized in Table 3. Briefly, 20 patients had PCI to
Table 1. Baseline Demographic and Clinical Characteristics of
Study Patients
Age, yrs 7012.5
Male/female 36/12 (75%)
Hypertension 140/90 mm Hg 33 (69%)
Hypercholesterolemia, LDL 130 mg/dl 19 (39%)
Diabetes mellitus, pre-existing 12 (25%)
Chronic renal failure, creatinine 1.5 mg/dl 8 (16%)
Smoking 25 (52%)
STEMI or new LBBB 22 (45%)
NSTEMI 26 (55%)
Cardiogenic shock/Killip class IV 22 (45%)
Logistic EuroSCORE 37.8921.80
GRACE score 21042.84
Values are mean SD or n (%).
EuroSCORE  European System for Cardiac Operative Risk Evaluation; GRACE  Global
Registry of Acute Coronary Events; LBBB  left bundle branch block; LDL  low-density
lipoprotein; NSTEMI  non–ST-segment elevation myocardial infarction; STEMI  ST-segmentelevation myocardial infarction.
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621LMCA and 1 other coronary artery (RCA: 4 [8%], LAD: 13
[27%], and LCX: 3 [6%]). Three patients had PCI to LMCA
and 2 other coronary arteries (LAD and LCX: 1 patient [2%],
RCA and LAD: 1 patient [2%], and RCA and LCX: 1 patient
[2%]). Of 34 (71%) patients with distal LMCA disease, 30
(88%) were treated with a provisional stenting technique,
whereas in the remaining 4 patients (12%), a “V” stenting,
simultaneous kissing stenting, or modified T stenting tech-
nique was used. The remaining 14 patients, who had ostial
and/or mid-shaft LMCA disease, were treated with a simple
stenting technique with or without prior balloon pre-dilation.
Coronary stents were used in 44 patients (92%): 29 patients
(61%) received DES, and 15 patients (31%) received bare-
metal stents. In 4 patients (8%), stent deployment was not
possible. In 1 case, the LMCA was severely calcified, and
despite rotablation and removal of a significant amount of
plaque, it proved impossible to deliver a stent, with a subop-
timal final angiographic result (stenosis50%). In the remain-
ing 3 patients, it was not possible to intervene on the LMCA
due to the inability to pass a guidewire and/or an angioplasty
balloon into the LAD or LCX because of heavy calcification
and/or an acute takeoff angle of the LMCA. Of these 3
remaining patients, 1 underwent CABG during hospitaliza-
Table 2. Angiographic Data
Ostial and/or body LMCA disease 14 (29%)
Distal LMCA disease 34 (71%)
LMCA disease only 4 (8%)
LMCA  1-vessel disease 11 (23%)
LMCA  2-vessel disease 17 (35%)
LMCA  3-vessel disease 16 (34%)
LAD stenosis 32 (66.6%)
LCX stenosis 21 (43.7%)
RCA stenosis (total) 26 (54%)
RCA occlusion 12 (25%)
Collateral circulation, Rentrop class
0–1 25 (52%)
2–3 23 (48%)
Stenosis severity Pre-PCI Post-PCI
100% 22 (46%) 0
75%–99% 21 (44%) 2 (4%)
50%–74% 5 (10%) 1 (2%)
20%–49% 0 (0%) 1 (2%)
20% 0 (0%) 44 (92%)
LMCA TIMI ﬂow grade Pre-PCI Post-PCI
0 7 (14.5%) 0
1 7 (14.5%) 1 (2%)
2 or 3 34 (71%) 46 (96%)
No reﬂow 0 (0%) 1 (2%)
Angiographic success 44 (92%)
LAD left anterior descending artery; LCX left circumflex artery; LMCA left main coronary
artery; PCI  percutaneous coronary intervention; RCA  right coronary artery;
TIMI  Thrombolysis In Myocardial Infarction.tion, and the other 2 died.Angiographic success (stenosis 20% in the ULMCA
and ostia of the main branches) was achieved in 44 (92%) of
the 48 patients, with partial success achieved in 1 case
(stenosis 50%) and procedural failure in 3 cases because of
technical difficulties outlined herein.
In-hospital outcomes. In hospital and long-term clinical
utcomes are illustrated in Table 4. In patients who pre-
ented in cardiogenic shock, in-hospital mortality was 32%,
hereas in patients who were hemodynamically stable at
resentation, in-hospital mortality was 11.5% (p  0.08).
en patients (20.8%) died in hospital, all secondary to
efractory cardiogenic shock and multiorgan failure. Uni-
ariate logistic regression analysis was performed in which
he effects of variables, including age 60 years, presenta-
ion with cardiogenic shock, DES use, diabetes mellitus,
lycoprotein IIb/IIIa inhibitor use, LMCA ostial lesion,
MCA distal lesion, significant RCA involvement, multi-
essel stenting, presence of collaterals, IABP use, clinical
resentation with STEMI, and angiographic success on
n-hospital mortality outcomes were studied. A summary
f the data is presented in Table 5. Multivariate stepwise
Table 3. Procedural Data
Total number of LMCA stents, n 51
BMS 20 (39%)
DES 31 (61%)
Mean number of LMCA stents per patient 1.06 0.48
Bifurcation stenting technique
Provisional stenting 27 (56%)
T-stenting 1 (2%)
Simultaneous kissing stenting 1 (2%)
V-stenting 2 (4%)
Rotablator without stenting 1 (2%)
Cutting balloon  stent 1 (2%)
Distal LMCA procedural failure 2 (4%)
Ostial LMCA procedural failure 1 (2%)
Optical coherence tomography use 1 (2%)
Intravascular ultrasound use 1 (2%)
Glycoprotein IIb/IIIa antagonists 25 (52%)
Aspirin 48 (100%)
Clopidogrel 36 (75%)
IABP 26 (54%)
Inotropic support 18 (37%)
Thrombectomy catheter 3 (6%)
PCI to LMCA only 25 (52%)
PCI to LMCA  LAD 13 (27%)
PCI to LMCA  LAD  LCX 1 (2%)
PCI to LMCA  LCX 3 (6%)
PCI to LMCA  RCA 4 (8.3%)
PCI to LMCA  RCA  LAD 1 (2%)
PCI to LMCA  RCA  LCX 1 (2%)
Values are mean SD or n (%).
BMS bare-metal stent(s); DES drug-eluting stent(s); IABP intra-aortic balloon pump(s);other abbreviations as in Table 2.
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622logistic regression analysis was performed in which vari-
ables included in the univariate analysis with a p  0.1
ere removed from the model. No variables were iden-
ified that were independently predictive of in-hospital
ortality.
In addition to the in-hospital deaths described herein,
here were 2 in-hospital MACE events due to a new
STEMI. In the first of these, there was definite ST in the
MCA (nonocclusive) and LCX (occlusive) in a patient
ho had undergone PCI to the LMCA with a T-stenting
Table 4. In-Hospital and 1-Year Clinical Outcomes
In-hospital outcomes
Angiographic success 44 (92%)
Death, total 10 (21%)
Reinfarction, total 2 (4%)
Stent thrombosis, deﬁnite 1 (2%)
MACE, total 12 (25%)
Repeat percutaneous target lesion revascularization 1 (2%)
Bypass graft surgery 1 (2%)
Death in patients with shock/Killip class IV 7 (32%)
Death in hemodynamically stable patients 3 (11.5%)
Stroke 0 (0%)
Out-of-hospital long-term outcomes
Mean follow-up duration 365 17.58
Death, total 4 (10.5%)
Reinfarction 4 (10.5%)
Stent thrombosis, possible 4 (10.5%)
MACE at 1 yr, total 7 (18.4%)
Repeat percutaneous target lesion revascularization 0 (0%)
Bypass graft surgery 3 (7.9%)
Death in patients with shock/Killip class IV 1 (2.6%)
Death in hemodynamically stable patients 3 (7.9%)
Values are n (%) or mean SD.
MACEmajor adverse cardiac event(s).
Table 5. Univariate Predictors of In-Hospital Mortality
Variable Odds Ratio (95% CI) p Value
Age 60 yrs 1.38 (0.29–6.44) 0.68
Cardiogenic shock 3.58 (0.80–16.05) 0.08
DES 0.68 (0.15–2.97) 0.61
Diabetes 0.36 (0.04–3.22) 0.36
GP IIb/IIIa inhibitor use 0.25 (0.05–1.33) 0.08
IABP 0.31 (0.07–1.40) 0.11
LMS distal 4.68 (0.53–41.07) 0.11
LMS ostial 0.31 (0.03–2.77) 0.24
Signiﬁcant RCA disease 1.35 (0.33–5.57) 0.68
Presentation with STEMI 0.23 (0.04–1.20) 0.06
Angiographic success 0.22 (0.03–1.83) 0.16
Collateral circulation presence 0.48 (0.27–1.48) 0.07
Multivessel stenting 1.92 (0.47–7.87) 0.36
CI  confidence interval; GP  glycoprotein; LMS  left main stem coronary artery; otherabbreviations as in Tables 1 and 3.technique. Percutaneous transluminal coronary angioplasty
was successfully used to treat the LMCA, but attempts at
recanalization of the LCX failed. Six months later, the
patient underwent elective CABG due to significant in-
stent restenosis within the LMCA. The second patient, in
whom the original attempt at PCI to LMCA ostium was
unsuccessful, developed chest pain with dynamic electrocar-
diogram changes and a raised troponin level 5 days fol-
lowing admission and subsequently underwent successful
CABG.
One-year outcomes. The overall mortality rate from the
ndex presentation up to 1-year following discharge was
9% (14 of 48 patients). From hospital discharge to 1-year
ollow-up, an additional 4 patients died due to possible ST:
had PCI to the distal LMCA, and 1 had PCI to the
MCA ostium and mid-LAD. Thus, the 1-year survival
ate of in-hospital survivors was excellent at 89.5%. Univar-
ate logistic regression analysis was performed in which the
ffects of variables, including age 60 years, presentation
ith cardiogenic shock, DES use, diabetes mellitus, glyco-
rotein IIb/IIIa inhibitor use, LMCA ostial lesion, LMCA
istal lesion, significant RCA involvement, IABP use,
linical presentation with STEMI, and angiographic success
ere studied on 1-year mortality outcomes. A summary of
he data is presented in Table 6. Multivariate analysis did
ot identify any variables that were independently predictive
f 1-year mortality.
The overall MACE rate from the index presentation up
o 1 year following discharge was 39.6% (19 of 48 patients).
he 1-year MACE rate for in-hospital survivors was 18.4%
nd comprised events in 7 patients: 4 were deaths as
utlined herein, and the remaining 3 patients underwent
ABG following demonstration of significant in-stent re-
tenosis on routine coronary angiography at 6 months after
he index event.
Table 6. Univariate Predictors of 1-Year Mortality
Variable Odds Ratio (95% CI) p Value
Age 60 yrs 1.32 (0.30–5.84) 0.71
Cardiogenic shock 1.90 (0.54–6.71) 0.32
DES 0.58 (0.16–2.16) 0.42
Diabetes 0.54 (0.10–2.95) 0.48
GP IIb/IIIa inhibitor use 0.24 (0.05–1.03) 0.06
IABP 0.25 (0.06–0.95) 0.04
LMS distal 1.75 (0.41–7.59) 0.45
LMS ostial 0.46 (0.08–2.48) 0.37
Signiﬁcant RCA disease 1.80 (0.50–6.50) 0.37
Presentation with STEMI 0.21 (0.05–0.91) 0.04
Angiographic success 0.38 (0.05–2.97) 0.35Abbreviations as in Tables 1, 3, and 5.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 6 , 2 0 1 1 Pappalardo et al.
J U N E 2 0 1 1 : 6 1 8 – 2 6 PCI in Patients With AMI and LMCA Occlusion
623Discussion
In one of the largest series to date describing the results of
urgent PCI to ULMCA, we report herein that emergency
PCI to a ULMCA culprit lesion in patients with ACS is a
feasible therapeutic option with acceptable MACE rates
and should be considered in patients presenting with AMI
in the acute setting. Primary PCI of the ULMCA is
technically feasible in most patients and has the advantage
of providing more rapid reperfusion compared with CABG,
with acceptable short- and long-term outcomes.
Our observed result of a 21% in-hospital mortality rate
compares favorably with those published previously for
similar patient cohorts, which varied between 33% and 58%
(19–24), despite the fact that 45% of our patients presented
in cardiogenic shock. We also demonstrate that patients
who present in cardiogenic shock have a trend toward a
higher in-hospital mortality rate than do those who are
hemodynamically stable (odds ratio: 3.58, 95% confidence
interval: 0.80 to 16.05; p  0.08). Other studies such as
those of De Luca et al. (19), Prasad et al. (22), Hurtado et
al. (23), and Jensen et al. (24) have demonstrated that
presentation with cardiogenic shock is independently asso-
ciated with mortality. Possible explanations for the lower
mortality rates observed in the current series compared with
those reported previously (19–22) include the lower pro-
portion of patients with cardiogenic shock at presentation in
the current study (45%) compared with the other studies
(63% to 92%). Indeed, in Lee et al. (29), the 1 study in
which a lower in-hospital mortality rate (8%) was reported,
the proportion of patients with cardiogenic shock at pre-
sentation was only 24%. Another potential explanation
relates to the proportion of patients with STEMI because
Jensen et al. (24) demonstrated worse outcomes associated
with STEMI presentation compared with those with
NSTEMI, although other investigators have shown no
differences (29). In the current series, only 45% of patients
presented with STEMI, whereas in other reports, the
proportion was considerably higher. Recently, data from the
GRACE registry has been published on ULMCA revascu-
larization in patients presenting with ACS (26). In this
cohort, 514 patients underwent PCI and 612 underwent
CABG, with an overall in-hospital mortality rate of 11%.
Patients presenting with cardiogenic shock had a mortality
rate of 40%. Although the GRACE registry data on
ULMCA revascularization are far larger than ours (514 vs.
48 patients, respectively), the 2 cohorts are very different.
Our series presents data on patients undergoing emergency
ULMCA revascularization within a few hours of arrival at
the interventional center. By contrast, less than one-half of
patients treated with a PCI strategy in the GRACE registry
underwent revascularization on the day of admission and
only 69% within 48 h. Furthermore, only a minority of
patients included in the GRACE registry presented withcardiogenic shock (5.1%) compared with 45% of patients in
the current study.
There is only limited data on emergency CABG in
patients with AMI due to significant ULMCA disease
(30,31). One study reported a 19% in-hospital mortality rate
in patients with ACS and significant LMCA disease who
underwent CABG (30). For the subgroup of patients
presenting with cardiogenic shock pre-operatively and de-
veloping a low cardiac output state and multiorgan failure
post-operatively, the in-hospital mortality rate was much
higher at 75% (30). Another study reported on 13 patients
with an AMI and significant LMCA stenosis who under-
went emergency CABG (6). In that study, the perioperative
mortality for the group as a whole was 46%, whereas for the
cardiogenic shock subgroup, it was higher at 53%. The
reported overall in-hospital mortality rate in the GRACE
registry for patients who underwent CABG for LMCA
disease was quite low at 5.4%. The corresponding mortality
rate for the subgroup of patients with cardiogenic shock was
also relatively low at 30%. It must, however, be emphasized
that only 5.1% of patients had CABG on the same day of
admission and 25% had CABG within 48 h. The median
delay from the time of admission to CABG revasculariza-
tion was 4.5 days. Furthermore, only 1.7% of these patients
were in cardiogenic shock at presentation. It is therefore
most likely that the surgically revascularized patients in the
GRACE registry represented a more stable cohort of
patients compared with patients in the current study.
Indeed, even within the GRACE registry, patients who
underwent CABG had significantly lower GRACE risk
scores than did those who underwent PCI and, therefore,
represented a more stable cohort of patients. When com-
paring PCI with CABG in the acute setting of AMI, it
must be remembered that clinical outcome is improved with
any revascularization versus medical therapy alone. Further-
more, among revascularization patients, a treatment bias
favoring performance of PCI rather than CABG in higher
clinical-risk patients prohibits direct comparison between
the 2 revascularization modalities and despite differences in
patient groups and decisions for treatment, ULMCA PCI
in STEMI is associated with similar survival rates compared
with CABG (25).
AMI due to ULMCA disease is often complicated by
hemodynamic instability, frank cardiogenic shock, or resus-
citated cardiac arrest. In such critically ill patients, prompt
and complete reperfusion of the occluded vessel is essential
to improve prognosis. Because cardiothoracic surgeons are
generally reluctant to undertake emergency CABG on
hemodynamically unstable patients, particularly in the con-
text of an AMI, PCI has become the preferred mode of
revascularization in patients with ACS due to ULMCA
disease. This has recently been illustrated in the GRACE
registry, where over its 8-year period (2000 to 2007), and
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624despite relatively constant GRACE risk scores, the rate of
CABG had fallen from 45% to 25%, with a corresponding
rise in the rate of PCI from 18% to 40% (26).
PCI to ULMCA is often a complex procedure, requiring
a combination of skill and speed, particularly in the acute
setting when patients are often hemodynamically unstable.
In such cases, every attempt should be made to keep the
procedure as simple as possible. Consequently, in this study,
most bifurcation lesions were treated with a provisional side
branch stenting technique, with only 4 cases (8%) requiring
an alternative technique, such as V-stenting, simultaneous
kissing stenting, or modified T-stenting. The provisional side
branch stenting technique is the simplest PCI strategy for
LMCA bifurcation lesions. Other studies of patients with
STEMI undergoing emergent PCI to a culprit LMCA lesion
have also reported the preferential use of a single stent strategy,
reserving more complex strategies, such as V-stenting and
T-stenting, for a minority of cases (24). In addition to simplicity,
a provisional side branch stenting strategy, compared with a
double-vessel stenting strategy, has been shown to be associated
with lower restenosis rates (32–34).
The use of aspiration/thrombectomy catheters is com-
monplace in primary PCI (35) and TAPAS (Thrombus
Aspiration During Percutaneous Coronary Intervention in
Acute Myocardial Infarction Study) has shown that the use
of thrombectomy during primary PCI is associated with a
decrease in cardiac death or reinfarction at 1 year (36). In
our registry, the use of thrombectomy devices was limited to
3 of 22 patients (13.6%) undergoing primary PCI for
STEMI; in the remaining primary PCI cases, thrombus was
managed pharmacologically or mechanically using angio-
plasty balloons. Many of the patients included in this series
were hemodynamically unstable; therefore, the main objec-
tive in these cases was the rapid establishment of antegrade
coronary flow, avoiding any steps, including the routine use
of thrombectomy devices, that may prolong the procedure,
with potentially an unfavorable influence on patient out-
come. Other recent studies have similarly reported low rates
of thrombectomy device use in STEMI patients undergoing
PCI to LMCA (24), presumably for similar reasons.
The anatomic pattern of restenosis after distal LMCA
stenting is mostly focal and often involves the left circumflex
ostium (37), where an acute angle of takeoff may predispose
to malapposition of stent struts. Consequently, we would
recommend that single-stent strategies be used for distal
LMCA lesions where possible, to minimize the risks of ST
and restenosis.
We recorded 1 case of definite in-hospital ST and 4 cases
of possible late ST, with a combined 1-year rate of 10%.
This relatively high rate of ST may be due in part to the
high-risk profile of the patient cohort studied, and in part to
the lack of systematic optimization of the final stent result
with intravascular ultrasound/optical coherence tomogra-
phy. The latter, however, is often precluded by the patient’shemodynamic instability. It remains possible that had more
powerful antiplatelet agents been used in this cohort, the
observed rates of ST would have been lower (38).
According to the 2009 American College of Cardiology/
American Heart Association STEMI treatment guidelines
for PCI (39), stenting can be considered in patients with
anatomic and clinical conditions that predict an increased
risk of adverse surgical outcomes (Class IIb). However,
randomized trials have been and/or would be too complex to
set up in view of the instability of these patients as well as
the logistic complexities and treatment biases that favor one
therapy over the other. However, fundamental issues specific
to PCI in the treatment of UMLCA in the acute setting that
should be considered include: 1) possible advantages of
PCI with respect to more rapid reperfusion compared
with CABG; 2) efficacy of DES; 3) technical consider-
ations regarding the treatment of the distal ULMCA;
4) duration of dual antiplatelet therapy; 5) role of IABP
for hemodynamic support; and 6) possible advantages of
PCI with respect to lower risk of stroke compared with
CABG (25).
Study limitations. This report retains all the well-recognized
limitations of a retrospective, nonrandomized study. PCI
was not performed according to standardized protocols, and
the interventional strategy was chosen according to operator
preference. Nonetheless, the study represents a “real-world”
cohort of patients undergoing real-world interventional
treatment, and, therefore, reflects current practice more
reliably than that in the pivotal, published clinical trials. The
number of patients in this series is small, although this
reflects the relative rarity of ULMCA-related infarcts.
Furthermore, such small cohorts with a small number of
endpoints limit the strength of multivariate analyses that
should be viewed as hypothesis-generating in the current
context. Finally, routine follow-up angiography was per-
formed in nearly one-half the patients, and this may have
artificially raised the number of repeat interventions.
Conclusions
ULMCA culprit disease in patients presenting with ACS is
rare but is associated with high in-hospital mortality,
especially in those presenting with cardiogenic shock. We
demonstrate in this study that PCI is a feasible treatment
option in these patients and is a reasonable alternative to
surgical revascularization. Despite the extensive use of
hemodynamic support, a 21% in-hospital mortality rate was
observed in this study, although for those who survive to
hospital discharge, a much better prognosis is recorded, with
an 10.5% mortality rate at 1 year. Without randomized trial
data, the decision to perform CABG or PCI in AMI
patients with ULMCA disease is difficult, and the decision
needs to be individualized, taking into consideration poten-
tial risks involved for each treatment strategy. Ultimately,
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625randomized, controlled trials will be needed to further
elucidate the optimal treatment strategy, although PCI is
both feasible and associated with acceptable outcomes as
demonstrated in this study.
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